Servier Signs €1bn-Plus AI Pact with Iktos
Servier has inked a partnership with Paris‑based Iktos valued at over €1 billion to harness generative AI and robotics for small‑molecule drug discovery. The alliance targets oncology and neurological diseases and follows a recent $888 million AI deal with Insilico Medicine. Iktos’ platform promises to cut discovery timelines from five years to two or less, while improving candidate quality. The collaboration will feed AI‑generated molecules into Servier’s pre‑clinical and clinical pipelines, expanding its R&D portfolio.
The Critical Need for Digital Transformation in the Peptide and API Sectors
Saharsh Davuluri, Vice Chairman of Neuland Labs, warns that peptide and API manufacturing must undergo rapid digital transformation by 2026 to keep pace with modern biologics. He highlights the surge in peptide therapeutics across cardiovascular, dermatology, and CNS indications, creating...
Coffee as a Staining Agent Substitute in Electron Microscopy
Researchers at Graz University of Technology have demonstrated that ordinary espresso can replace the hazardous uranyl acetate as a staining agent for electron microscopy. In side‑by‑side tests on ultrathin mitochondrial sections, coffee‑treated samples produced contrast equal to or better than...
Gene Therapy, Rare Diseases, and Transfer RNA
Tevard Biosciences showcased its suppressor tRNA platform at the J.P. Morgan Healthcare Conference, presenting pre‑clinical data that rescued full‑length dystrophin in Duchenne muscular dystrophy models and restored titin in dilated cardiomyopathy models. The technology corrects premature termination (nonsense) codons, enabling...
From Nuclear Winter to Renewal: Biotech Investing for 2026
The Denatured podcast episode "From Nuclear Winter to Renewal: Biotech Investing for 2026" features Sofinnova’s Maha Katabi and Ally Bridge’s Andrew Lam discussing a shift from a prolonged funding chill to a robust M&A environment. Guests highlight that 2026 will...
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Parabilis Medicines announced an oversubscribed $305 million Series F financing, the largest of a busy Thursday for biotech fundraises. The capital will accelerate development of its lead peptide drug zolucatetide, which disrupts the β‑catenin/TCF transcription complex in rare and solid tumors. Parabilis...
Court Blocks HHS' 340B Rebate Programme Pilot
U.S. federal judges in the First Circuit upheld a Maine injunction that blocks the Health Resources and Services Administration’s pilot to replace upfront 340B drug discounts with post‑sale rebates. The decision keeps hospitals from having to purchase ten high‑volume medicines...
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
Venture capital into Massachusetts biopharma fell to $6.85 billion in 2025, the lowest level since 2019, as a cautious IPO market and investor reluctance dampened the first half. Despite the slump, 60% of the year’s funding arrived in the back half,...
Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference
Medable unveiled its Trial Master File (TMF) AI agent, a new module of the Agent Studio platform, at the JP Morgan Healthcare Conference. The agent automates document intake, classification, and metadata extraction before a one‑click upload to eTMF systems such as...
Ollin’s Drug Clears Retinal Disease Better than Roche’s Vabysmo in Phase 1b Trial
Ollin BioSciences announced Phase 1b data showing its bispecific antibody cleared retinal disease more effectively than Roche's Vabysmo. The early‑stage trial, initiated four months ago, enrolled a modest cohort and reported a favorable safety profile. Efficacy signals suggest superior anatomical...
Inside Doctronic's Experiment to Allow AI to Refill Prescriptions
Doctronic, a digital health platform, launched a pilot that lets an artificial‑intelligence engine automatically refill chronic‑care prescriptions. The AI cross‑checks patient records, insurance eligibility, and dosage guidelines before submitting orders to partner pharmacies. Early data show a 30% reduction in...
Synaffix and Sidewinder Agree to Advance Next-Generation Bispecific ADC Development
Synaffix, a Lonza company, and Sidewinder Therapeutics have signed a multi‑target licensing agreement to co‑develop first‑in‑class bispecific antibody‑drug conjugates (ADCs) for solid‑tumor indications. The deal gives Sidewinder access to Synaffix’s GlycoConnect antibody‑conjugation, HydraSpace polar spacer, and toxSYN linker‑payload technologies, while...
Study Finds Weight Returns More Quickly in GLP-1 Users
A new BMJ meta‑analysis of 37 studies involving over 9,000 adults shows that weight lost with GLP‑1 agonists such as Wegovy and Mounjaro is regained rapidly after treatment stops, at about 0.8 kg per month. This rebound rate is four times...
Tessera Therapeutics to Lay Off 90 Employees, According to Document
Tessera Therapeutics, a heavily funded gene‑editing startup, announced plans to lay off roughly 90 employees. The cuts represent a significant reduction in its workforce, signaling a shift in the company’s growth trajectory. The layoffs come as the biotech sector faces...
GSK, Noetik Sign Cancer Deal on AI Virtual Cell Models
GlaxoSmithKline (GSK) has entered a multi‑million‑dollar agreement with AI‑driven biotech Noetik to license its virtual cell models for cancer research. The partnership gives GSK access to Noetik’s proprietary AI simulations that predict cellular responses, allowing the pharma giant to evaluate...
Hengrui Gets First OK for a PD-L1/TGF-Beta Drug for Cancer
Jiangsu Hengrui Pharma secured China’s first approval for retlirafusp alfa, a bispecific PD‑L1/TGF‑beta fusion protein, as a frontline treatment for advanced gastric and gastro‑esophageal junction adenocarcinoma. The decision follows the phase 3 RELIGHT trial, which demonstrated a 34% overall‑survival gain versus...
Cas12a3 CRISPR System Targets tRNA Without Destroying Host Cell
Researchers at Utah State University identified a novel CRISPR nuclease, Cas12a3, that selectively cleaves the 3′ CCA tails of transfer RNAs, halting protein synthesis without damaging host DNA. Unlike Cas9, which makes a single cut in DNA, Cas12a3 is activated...
Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs
Biotech startup Diagonal Therapeutics secured $125 million in a Series B financing, bringing its total capital raised since 2024 to over $250 million. The funding will advance its lead candidate, DIAG723, a clustering antibody designed to reactivate the ALK1 pathway...
Blood Test Reveals Risk of Multimorbidity
A study by Karolinska Institutet identified a handful of blood biomarkers that reliably predict multimorbidity risk in people over 60. Researchers measured 54 markers and found seven, especially five metabolic indicators, linked to disease count, patterns, and progression speed. The...
The Top 12 Companies Hiring in Biopharma Now
BioSpace’s December hiring report shows a 10 % month‑over‑month drop in active job postings and a 16 % year‑on‑year decline versus December 2024, reflecting typical holiday‑season slowdown. A noticeable surge in postings during the first week of January signals that hiring momentum is...
Biopharmas Axed 47% More Employees Year Over Year
Biopharma layoffs surged 47% year‑over‑year in 2025, affecting roughly 42,700 employees, as capital tightening forced both early‑stage and large firms to cut staff. The wave was driven by investor pull‑back after biotech failures, prompting leaner operations and accelerated M&A activity....
Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
Strategic outsourcing through CROs and CDMOs is reshaping biopharma pipelines, linking discovery, formulation, and early‑phase manufacturing into seamless workflows. By tapping external expertise, companies can accelerate complex modalities such as cell and gene therapies, RNA medicines, and next‑generation biologics. Integrated...
Novel Gene Therapy Approach Targets Pain Centers in the Brain
Researchers at the University of Pennsylvania have unveiled the first central‑nervous‑system‑targeted gene therapy designed to relieve chronic pain by modulating cortical opioid circuits. Using an AI‑driven mouse model, they identified a persistent affective pain signature that morphine reverses, then engineered...
Alumis’ Phase III TYK2 Data Intensify Psoriasis Efficacy Contest
Alumis announced Phase III results for its oral TYK2 inhibitor envudeucitinib in moderate‑to‑severe plaque psoriasis. The trial met its primary endpoint, with 71% of patients achieving PASI‑90 at week 16, outperforming the active comparator and matching or exceeding data from...
$1B-Plus Biotech Takeouts: 2025 Biggest Year in Last Decade
Biotech M&A in 2025 saw a surge in mega‑transactions, with deals exceeding $1 billion accounting for more than half of all takeouts. The total value of these large deals topped $10 billion, marking the strongest year for billion‑dollar biotech acquisitions in the...
Delay Discounting Correlates with Depression but Does Not Predict Relapse After Antidepressant Discontinuation
The AIDA longitudinal study examined whether delay discounting could predict depressive relapse after antidepressant discontinuation. While patients with remitted major depressive disorder displayed modestly higher discount rates than healthy controls and discounting correlated with HAM‑D scores, baseline discounting and changes...
Shared Neurogenetic Architecture Links Adolescent Neurodevelopmental Deviations to Adult Psychopathological Procrastination
A new study demonstrates that the same genetic factors shaping adolescent brain development also predispose individuals to pathological procrastination in adulthood. Using twin data, high‑resolution MRI and normative modeling, researchers identified overlapping neurogenetic signatures in cortical and subcortical regions linked...
Trump Administration Backs Pediatric PRVs
The Trump administration is lobbying Congress to approve the Mikaela Naylon Give Kids a Chance Act, which would reauthorize the rare pediatric disease priority voucher (PRV) program. The bill has already cleared the House of Representatives. In the Senate, Senator...
Lilly Snaps up Ventyx for $1.2B in Pursuit of Oral Immune Drugs
Eli Lilly agreed to acquire Ventyx Biosciences for $1.2 billion, paying a 62 % premium to secure the oral NLRP3 inhibitor VTX3232. The drug showed a 64 % reduction in a cardiac‑risk biomarker and synergistic effects with semaglutide in obesity‑related trials. The purchase expands...
AI Tool Can Take a Cattle's Temperature with only a Photo
Researchers at the University of Arkansas unveiled CattleFever, an AI system that estimates a calf’s body temperature from a single RGB‑thermal photo. The model, trained on the newly released CattleFace‑RGBT dataset with 13 facial landmarks, achieved temperature predictions within one...
Ribosomal Engineering Creates 'Super-Probiotic' Bacteria with Enhanced Immune Activation
Researchers at Shinshu University used ribosome engineering to create a Lacticaseibacillus rhamnosus GG strain with a K56N mutation in ribosomal protein S12. The mutant displays markedly more surface moonlighting proteins, especially GAPDH, leading to double the adhesion to intestinal cells...
Sulfolobus Islandicus: Expanding the Genetic Toolkit for Drug Delivery and Biotechnology Applications
University of Illinois researchers used the CRISPR‑COPIES pipeline and multi‑omics profiling to map chromosomal integration hotspots in the hyperthermophilic archaeon Sulfolobus islandicus. They identified 66 crRNAs targeting 21 intergenic regions and functionally validated eight sites with a lacS‑β‑galactosidase reporter. Overexpressing...
Advances in Extracellular Vesicle Separation and Isolation
Finnish researchers reviewed the latest size‑, charge‑, and affinity‑based methods for extracellular vesicle (EV) isolation as exosome therapeutics move toward clinical use. They highlighted emerging size‑based techniques such as deterministic lateral displacement (DLD) with thermally‑oxidized tapered structures and viscoelastic microfluidic...
Fungus with Hidden Talent Leads to Rethink on Making Classic Cancer Drug
Researchers have identified an endophytic fungus, *Colletotrichum siamense*, living inside the Madagascar periwinkle that can synthesize the chemotherapy drug vinblastine. The fungus produced the compound at a modest 138 µg per liter, matching the plant‑derived molecular signature. Laboratory tests confirmed that...
Automated Lab of the Future May Herald Lower-Cost Therapies
German researchers at TU Berlin’s KIWI‑biolab have built a self‑driving laboratory that uses robotics, AI and bioinformatics to automate the development of new biomolecules. The system runs E. coli cultures in 10‑100 mL bioreactors, validates processes up to 100 L, and relies on...
CCGT Sector Needs Purpose-Built Quality Management Systems
Researchers argue that traditional quality management systems, built for large‑scale protein drugs, are ill‑suited for cell and gene therapy (CGT) manufacturing. Manual, paper‑based processes have evolved into fragile eQMS platforms that struggle with the lean, modular nature of CGT production....
Behind the Headlines Episode 31: Optimism, Opportunity, Optimization of COGs & Organizational Streamlining
In the Behind the Headlines Episode 31, veteran pharma leader Deborah Dunsire declares a "golden era" for biological sciences, driven by targeted therapies such as GLP‑1s and emerging tools like AI and quantum computing. She stresses the need for fact‑based communication...
CRISPR Discovery Could Lead to Single Diagnostic Test for COVID, Flu, RSV
Utah State University researchers have uncovered a novel function of the bacterial immune protein CRISPR‑Cas12a3 that directly targets RNA and cleaves tRNA tails, halting viral protein production without damaging host DNA. Published in Nature, the work shows Cas12a3 can be...
5 FDA Decisions to Watch in the First Quarter of 2026
Eli Lilly’s oral GLP‑1 candidate orforglipron received a national‑priority voucher, accelerating its FDA review and threatening Novo Nordisk’s recent oral Wegovy launch. Disc Medicine’s repurposed schizophrenia drug bitopertin is on the brink of approval for the rare disease erythropoietic protoporphyria,...
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
GSK and Ionis reported that their antisense oligonucleotide bepirovirsen achieved a functional cure in the Phase III B‑Well 1 and B‑Well 2 chronic hepatitis B trials. The drug met its primary efficacy endpoint and all ranked secondary endpoints, showing statistically significant cure rates without...
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
Jazz Pharmaceuticals reported Phase III HERIZON‑GEA‑01 data showing its bispecific HER2 antibody Ziihera dramatically improves outcomes in first‑line HER2‑positive gastroesophageal adenocarcinoma. In a trial of more than 900 patients, Ziihera combined with chemotherapy cut the risk of progression or death by...
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
Pfizer has signed a multi‑year agreement with Cartography Biosciences to discover novel tumor‑selective antigens. The deal provides up to $65 million in upfront and near‑term milestones, with potential total payments exceeding $800 million if all options are exercised. Cartography will employ its...
Drone Monitoring Helps Dolphins
A Flinders University team demonstrated that drones equipped with infrared thermal cameras can accurately measure surface temperature and respiration rates of bottlenose dolphins. Analyzing more than 40,000 thermal images, researchers found optimal accuracy at 10‑15 m altitude directly overhead. The method...
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Novo Nordisk introduced its first oral GLP‑1 obesity treatment, Wegovy pill, priced at $149 per month for lower doses. Eli Lilly is eyeing a March approval for its oral weight‑loss candidate orforglipron, positioning it as a catalyst to more than double...
Bayer and Cradle Enter Collaboration to Enhance AI-Enabled Antibody Discovery and Optimization
Pharma giant Bayer has signed a three‑year strategic collaboration with AI‑driven protein‑engineering firm Cradle to embed its generative platform into Bayer’s antibody R&D. The integration aims to accelerate lead generation, improve potency, safety and manufacturability, and reduce the number of...
BIO Warns of Risks From Change to CDC’s Vaccine Recommendations
The U.S. Centers for Disease Control and Prevention announced it will now recommend only 11 of the 17 childhood vaccines it previously endorsed, moving six vaccines to a high‑risk or provider‑consultation model. The Biotechnology Innovation Organization (BIO) condemned the shift...
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
Biotech investors anticipate a rebound in 2026, driven by a wave of M&A activity and larger private financing rounds observed in late 2025. High‑profile deals such as Pfizer’s $10 billion acquisition of Metsera and AbbVie’s $10.1 billion purchase of ImmunoGen signal renewed...
The New Subcutaneous (SC) Landscape: Adapting Drug Delivery for Biologics Administration at Home
The pharmaceutical sector is rapidly transitioning high‑value biologics from clinic‑based IV infusions to at‑home subcutaneous (SC) self‑administration. Datwyler’s upcoming event will dissect market forces behind this shift, emphasizing challenges such as drug viscosity, volume limits, and component compatibility. Speakers will...
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
BioSpace’s 2026 NextGen list spotlights 15 early‑stage life‑science startups that secured seed or Series A financing despite a 2025 capital crunch. The cohort includes rare‑disease pioneers and innovators tackling cardiovascular, oncology, and genetic therapies. Notable deals feature Light Horse’s $62 million Series A...
Arrowhead siRNA Data in Obesity Mark POC for Adipose Delivery
Arrowhead Pharmaceuticals announced proof‑of‑concept data showing its siRNA platform can be delivered directly to adipose tissue, producing notable weight loss in preclinical obesity models. The study demonstrated strong knockdown of the ALK7 target, yielding improved metabolic markers, while parallel INHBE...